- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06046976
Piezosurgical vs Conventional Exodontia Surgery in Healthy and Patients With Diabetes Mellitus Type 2 (PCSDMT2)
October 30, 2023 updated by: Bozidar Brkovic, DDS, MSc, PhD, Professor, University of Belgrade
Evaluation of Piezosurgical vs Conventional Surgery Approach During Complex Exodontia in Healthy and Patients With Diabetes Mellitus Type 2
This study will evaluateand compare intraoperative and postoperative clinical parameters related to discomfort and wound heeling, as well as laboratory wound healing parameters after piezosurgical and conventional surgery approach during complex exodontia in healthy and patients with Diabetes Mellitus Type 2
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Belgrade, Serbia, 11000
- University of Belgrade Faculty of Dental Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- multiple multi-rooted teeth indicated for extraction
- controlled DMT2
Exclusion Criteria:
- HbA1c >7%
- chronic orofacial pain and infection in orofacial region
- alcohol and tobacco consumption
- pregnant women and nursing mothers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Healthy
|
exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
|
Experimental: Diabetes mellitus type 2
|
exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of osteotomy
Time Frame: from the start of procedure to the end of performing osteotomy
|
from the start of procedure to the end of performing osteotomy
|
MicroRNA 21 (Mir-21) expression
Time Frame: during the first 24 hours after intervention
|
during the first 24 hours after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of tooth sectioning
Time Frame: from the beginning of tooth sectioning to the end of tooth sectioning
|
from the beginning of tooth sectioning to the end of tooth sectioning
|
|
Total exodontia time
Time Frame: from the beginning of surgical procedure to the end of tooth extraction
|
from the beginning of surgical procedure to the end of tooth extraction
|
|
Pain intensity
Time Frame: during the first 24 hours after intervention
|
Numerical Rating Scale, measuring pain intensity ranging from 0 (no pain) to 10 (the worst pain imaginable)
|
during the first 24 hours after intervention
|
Healing Index Score
Time Frame: within 21 days after procedure
|
3 scoring levels for each of the 4 parameters considered: tissue color (1 = 100% of gingiva pink; 2 = <50% of gingiva red, hyper- emic, movable; 3 = >50% of gingiva red, hyperemic, movable), color and consistency of the healing tissue (1 = close grained, pink; 2 = soft, red; 3 = fragile, greenish or grayish), suppuration (1 = absent; 2 = absent but pronounced amount of plaque around socket walls; 3 = pronounced), and bleeding (1 = absent; 2 = induced by palpation; 3 = spontaneous).
Thus, the scoring scale ranged from 4, corresponding to excellent healing, to 12, indicating severely impaired healing.
|
within 21 days after procedure
|
First postoperative pain report
Time Frame: within 24 hours after procedure
|
time between the end of procedure and first pain experienced by the patient measured in minutes
|
within 24 hours after procedure
|
First analgesic consumption
Time Frame: within 24 hours after procedure
|
time from the end of the procedure until first analgesic consumption measured in minutes
|
within 24 hours after procedure
|
Clinical appearance of gingival tissue
Time Frame: within 7 days after procedure
|
clinical appearance of the soft tissues (Visual Analogue Scale 0 to 3, according to the color and presence of edema and bleeding; ie, 0, normally pink, not edematous; 1, pink-red, slightly edematous; 2, red, edematous; and 3, red, edematous, bled easily when touched
|
within 7 days after procedure
|
Residual Socket Volume
Time Frame: within 21 days after procedure
|
the residual socket volume (RSV) is the fraction of the postextraction original cavity still open at each follow-up session (t = 3, 7, 14, and 21 days), computed as the ratio of mesiodistal (MD), bucolingual (BL) and socket depth (SD) at the follow-up session to the baseline value (t=0), measured after extraction (perfect closure corresponds to RSV = 0.00)
|
within 21 days after procedure
|
Postextraction wound epithelization
Time Frame: within 21 days after procedure
|
Epithelialization was measured as bucolingual and mesiodistal diameter of the extraction socket during the follow-up (3, 7, 14 and 21 postoperative day), expressed in millimeters
|
within 21 days after procedure
|
Vascular Endothelial Growth Factor (VEGF) level
Time Frame: within 24 hours after intervention
|
detected by Enzyme-Linked Immunosorbent Essay method
|
within 24 hours after intervention
|
Matrix Metalloproteinase 9 (MMP9) level
Time Frame: within 24 hours after intervention
|
detected by Enzyme-Linked Immunosorbent Essay method
|
within 24 hours after intervention
|
Phosphatase and Tensin Homolog (PTEN) level
Time Frame: within 24 hours after intervention
|
detected by Enzyme-Linked Immunosorbent Essay method
|
within 24 hours after intervention
|
Superoxide Dismutase(SOD) enzyme activity (%)
Time Frame: within 24 hours after intervention
|
Activity level detected by spectrophotometry using SOD Assay kit
|
within 24 hours after intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Milan Vucetic, DDS PHD, University of Belgrade Faculty of Dental Medicine
- Study Director: Bozidar Brkovic, DDS PhD, University of Belgrade Faculty of Dental Medicine
- Principal Investigator: Marija S Milic, DDS PhD, University of Belgrade Faculty of Dental Medicine
- Principal Investigator: Jelena Roganovic, DDS PhD, University of Belgrade Faculty of Dental Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 13, 2022
Primary Completion (Actual)
October 10, 2023
Study Completion (Actual)
October 10, 2023
Study Registration Dates
First Submitted
December 2, 2022
First Submitted That Met QC Criteria
September 13, 2023
First Posted (Actual)
September 21, 2023
Study Record Updates
Last Update Posted (Actual)
October 31, 2023
Last Update Submitted That Met QC Criteria
October 30, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 36/06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on piesosurgical extraction
-
Rachel LittleCompleted
-
Marmara UniversityRecruitingInferior Alveolar Nerve InjuriesTurkey
-
Azienda Ospedaliera di BolzanoUnknownImpacted Third Molar ToothItaly
-
Cairo UniversityRecruitingMalocclusion | Crowding, Tooth | Long Face SyndromeEgypt
-
Università degli Studi dell'InsubriaCompletedPostoperative Complications | Postoperative Pain | Intraoperative Complications | Patients SatisfactionItaly
-
Virginia Commonwealth UniversityNational Institute on Aging (NIA)Enrolling by invitation
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedUrinary Incontinence | Uterine Prolapse | Fecal IncontinenceNorway
-
Universidade Federal FluminenseCompletedTooth Extraction Status NosBrazil
-
Istituto Clinico HumanitasRecruitingRectal Cancer | SurgeryItaly
-
Ain Shams UniversityRecruiting